Aksia Capital, a private equity firm, completed the acquisition of a 75% stake in MIR, a global medical device and software company for €36m. "We need greater accessibility to tools that allow us to personally assess our state of health now more than ever. In particular, the health of our lungs and overall respiratory function. MIR is playing a key role in this picture, with very affordable solutions that enable the ability for our healthcare providers to manage their patients with pulmonary-related issues remotely. In addition, a new Smart line in the field of cardiology will be launched later this year," Paolo Boschetti Sacco, MIR CEO.